Steven Findlay

Long-Stalled FDA Reform Sits On Senate’s Lame-Duck Calendar

KHN Original

The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.